Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
561-580 of 2,120 trials

Cystectomy Complications: Antifungal Treatment Study

We are testing whether a new antifungal medication can help reduce complications after radical cystectomy. This study compares the medication to a placebo to see if it makes a difference.

Fungal Infection3-6 monthsMonitoring phase (IV)Standard MedicinesInfectious DiseasesUrology

Limited-Stage Small-Cell Lung Cancer: Tarlatamab Study

We are studying whether tarlatamab can improve survival and prevent disease progression in patients with limited-stage small-cell lung cancer after chemoradiation therapy. Participants will receive either tarlatamab or a placebo to compare their effects.

Limited-Stage Small-Cell Lung CancerConfirmation phase (III)Investigational MedicinesCost ReimbursementOncology

Mirikizumab for Children with Ulcerative Colitis or Crohn’s Disease

We are studying the long-term effects of mirikizumab in children and adolescents with moderate-to-severe ulcerative colitis or Crohn’s disease. This research aims to see how well the treatment works for these conditions.

Crohn’s DiseaseUlcerative ColitisInflammatory Bowel DiseasesConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

Talquetamab: Reducing Oral Side Effects

We are testing ways to lessen taste changes caused by talquetamab in patients undergoing treatment. The goal is to find effective methods to improve the experience for those affected.

Multiple Myeloma>2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteInternal MedicineOncology

Breast Cancer Treatment: Chemotherapy vs. Endocrine Therapy

We are studying the effectiveness of chemotherapy compared to endocrine therapy for women with ER-positive HER2-negative metastatic breast cancer. This trial focuses on patients with specific health markers to determine the best treatment option.

Metastatic Breast Cancer>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesOncology

MK-5684 Therapies for Advanced Prostate Cancer

We are studying the safety and effectiveness of MK-5684-based treatments for men with metastatic castration-resistant prostate cancer. This research aims to find better options for managing this advanced stage of cancer.

Metastatic Castration-Resistant Prostate Cancer>2 yearsSafety phase (I)Efficacy phase (II)Standard MedicinesCost ReimbursementOncologyUrology

Obesity in Adolescents: Semaglutide Treatment Study

We are exploring whether a weekly injection of semaglutide can help adolescents with obesity lose weight more effectively than a placebo. This study also looks at the safety and overall health impacts of the treatment.

Obesity1-2 yearsMonitoring phase (IV)6-10 visitsInvestigational MedicinesPartially RemoteEndocrinologyPediatrics

Advanced Head and Neck Cancer: Volrustomig Treatment Study

We are studying whether volrustomig is safe and effective for adults with advanced head and neck cancer who have recently completed chemoradiotherapy without surgery. This trial compares the treatment to observation to see which approach may help patients more.

Unresected Locally Advanced Head and Neck Squamous Cell CarcinomaConfirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncologyOtolaryngology

Postoperative Pain Management After Cardiac Surgery: NSAIDs Study

We are investigating whether nonsteroidal anti-inflammatory drugs can help reduce pain after cardiac surgery. This study will also look at how these medications affect recovery and overall quality of life.

Postoperative Pain After Cardiac Surgery>2 yearsMonitoring phase (IV)Standard MedicinesCardiologyInternal Medicine

AUTO1 Treatment for Pediatric Blood Cancers

We are studying the safety and early effectiveness of AUTO1 in children with relapsed or refractory B cell acute lymphoblastic leukemia and aggressive mature B cell non-Hodgkin lymphoma. This trial aims to see how well the treatment works and how it can be safely administered.

B-cell Acute Lymphoblastic LeukemiaAggressive Mature B-cell Non-Hodgkin Lymphoma>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesHematologyOncology

Melanoma Treatment: Pembrolizumab with New Agents

We are studying the safety and effectiveness of pembrolizumab alone or with new investigational treatments for people with melanoma. This research aims to find better options for managing this type of skin cancer.

Melanoma>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Lung Cancer: V940 and Pembrolizumab Study

We are studying the effects of a new treatment combining V940 with pembrolizumab for patients with resectable stage II to IIIB lung cancer. The goal is to see if this combination improves disease-free survival compared to a placebo.

Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)16-20 visitsInvestigational MedicinesCost ReimbursementOncologyPulmonology

Long-Term Safety Study of Ongoing Treatment with Study Drugs

We are providing continued access to a study drug for patients who are benefiting from it. The goal is to monitor its long-term safety as they continue treatment.

Metastatic Breast CancerMetastatic Non-Small Cell Lung CancerHER2 Positive Breast CancerConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Plaque Psoriasis: Bimekizumab Study

We are exploring how bimekizumab affects gene expression in people with moderate to severe plaque psoriasis. The study also looks at the safety of this treatment for those with or without psoriatic arthritis.

Plaque PsoriasisPsoriatic Arthritis>2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesDermatologyRheumatology

MB-CART2019.1 Therapy for Pediatric B-Cell Neoplasms

We are studying how safe and effective MB-CART2019.1 is for children and teens with relapsed or refractory B-cell cancers. This research aims to find better treatment options for those who haven't responded to other therapies.

Refractory or Recurrent B-cell Lymphoma1-2 yearsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncologyPediatrics

Uterine Leiomyosarcoma: Post-Operative Chemotherapy Study

We are investigating whether adding chemotherapy after surgery helps patients with high-risk localized uterine leiomyosarcoma avoid relapse. This study compares the new treatment approach to standard observation care.

Uterine LeiomyosarcomaEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

Tourette Disorder: Serotonin and Impulsivity Study

We are investigating how serotonin receptors relate to impulsivity in adults with Tourette's syndrome. This study may help us understand brain activity and behavior during treatment.

Tourette Syndrome>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesNeurologyPsychiatry

Advanced Urothelial Carcinoma: MK-2870 with Enfortumab Vedotin

We are studying a new treatment combining MK-2870 with Enfortumab Vedotin and Pembrolizumab for patients with advanced bladder cancer. The goal is to assess safety and how well it works compared to existing options.

Bladder Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Immuno-OCT Imaging: Safety and Feasibility Study

We are exploring a new imaging technique using a tracer for patients undergoing endoscopy. The goal is to determine if this method is safe and effective for better visualization during procedures.

Barrett's EsophagusColon CarcinomaGastrointestinal DysplasiaSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementGastroenterologyOncology

Melanoma, NSCLC, and Cervical Cancer: ANV419 vs High-Dose IL-2

We are studying whether a new treatment (ANV419) is safer and improves outcomes compared to high-dose IL-2 for patients after tumor-infiltrating lymphocyte therapy. This trial also looks at quality of life and patient experiences.

Advanced Solid Tumors>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology